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addition of bevacizumab to irinotecan improves outcomes 
regardless of  K-ras mutational status. Bevacizumab has a 
well-established safety profile and the toxicities associated 
with its use are usually mild in severity and easily manage-
able.  Conclusions: Addition of bevacizumab to irinotecan-
containing regimens is an effective therapy option for the 
treatment of metastatic colorectal cancer. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 In Europe, there was an estimated 412,900 new cases 
of colorectal cancer (CRC) diagnosed in 2006, with ap-
proximately 207,400 CRC-related deaths, representing the 
second highest cancer mortality rate  [1] . Approximately 
25% of CRC patients present with synchronous metastat-
ic disease at first diagnosis, while an additional 40–50% 
develop metastases during the course of their disease  [2] .
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 Abstract 
 Objectives: Bevacizumab is a monoclonal antibody that di-
rectly inhibits vascular endothelial growth factor, a key regu-
lator of angiogenesis. Bevacizumab significantly improves 
progression-free and/or overall survival in metastatic colo-
rectal cancer in combination with standard chemotherapy. 
This review describes the evolution of irinotecan-based reg-
imens for metastatic colorectal cancer and evaluates the ad-
dition of bevacizumab to these regimens.  Methods: Litera-
ture searches from large publication databases (PubMed, 
ASCO, ASCO GI, ESMO) were performed to capture key data 
relevant to bevacizumab, irinotecan, and the treatment of 
colorectal cancer.  Results: Data from numerous large, multi-
national studies support the addition of bevacizumab to iri-
notecan-containing chemotherapy regimens for further 
 improvement in patient outcomes. In a randomized, place-
bo-controlled trial, addition of bevacizumab to irinotecan 
significantly improved progression-free survival, overall sur-
vival and response rate in patients with metastatic colorectal 
cancer, and these results are supported by a number of oth-
er clinical trials and observational studies. Furthermore, the 
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 Irinotecan has been available for the treatment of met-
astatic CRC (mCRC) since 1994 in the USA and 1995 in 
Europe. Irinotecan monotherapy was initially estab-
lished as a standard second-line therapy for mCRC after 
two large randomized phase III trials demonstrated that 
it improved overall survival (OS) compared with 5-fluo-
rouracil (5-FU)/leucovorin (LV) or best supportive care 
 [3, 4] . Subsequent phase III trials confirmed its efficacy as 
a first-line therapy in combination with bolus 5-FU/LV 
(IFL) or infusional 5-FU/LV (FOLFIRI)  [5, 6] .
 An alternative to 5-FU/LV is the 5-FU prodrug 
capecitabine (Xeloda  ), an oral fluoropyrimidine that is 
activated to 5-FU by thymidine phosphorylase primarily 
within the tumor cell. Clinical trials have shown that 
capecitabine has a comparable efficacy and safety profile 
to 5-FU in patients with mCRC  [7–9] . The efficacy and 
tolerability of capecitabine in combination with irinote-
can (CAPIRI) in first-line mCRC have been evaluated in 
several randomized controlled studies, with conflicting 
findings with regard to toxicity, despite using similar 
 regimens. In the Bolus, Infusional, or Capecitabine with 
Camptosar-Celecoxib (BICC-C) study, CAPIRI and 
FOLFIRI were not significantly different in terms of OS, 
but progression-free survival (PFS) was superior with 
FOLFIRI (7.6 vs. 5.8 months; p =  0.015)  [10] . Notably, 
higher rates of severe vomiting, diarrhea, and dehydra-
tion were observed in the CAPIRI group than in the FOL-
FIRI group. However, in the large CAIRO study, CAPIRI 
was associated with a PFS of 8.0 months with an accept-
able toxicity profile  [11] . In more recent studies, dose ad-
justments within newer CAPIRI regimens have led to im-
proved tolerability of this drug combination without loss 
of efficacy  [12, 13] .
 Although the addition of irinotecan to 5-FU- or 
capecitabine-based chemotherapy regimens extended 
patient survival, improvements in outcomes achieved 
with chemotherapy reached a therapeutic plateau, war-
ranting the need for alternative/additional active agents.
 The need for more active and better tolerated therapies 
in addition to the increased knowledge of the complex 
process of tumor biology and evolution has driven the 
research and development of novel agents. Bevacizumab 
(Avastin  ) is a humanized monoclonal antibody binding 
to vascular endothelial growth factor, a key mediator of 
angiogenesis. 
 Phase III clinical trials have demonstrated that the ad-
dition of bevacizumab to standard chemotherapy regi-
mens, such as those containing irinotecan or oxaliplatin, 
significantly improves PFS compared with chemothera-
py alone in patients with mCRC  [14, 15] . Furthermore, a 
recent meta-analysis of five randomized studies of be-
vacizumab incorporating a total of 3,103 patients with 
mCRC demonstrated that OS as well as PFS and overall 
response rate (ORR) were increased significantly with the 
addition of bevacizumab to chemotherapy (PFS, hazard 
ratio (HR) = 0.66, p  ! 0.01; OS, HR = 0.77, p  ! 0.01; ORR, 
relative risk = 1.5, p = 0.021)  [16] .
 Following US Food and Drug Administration (FDA) 
approval in 2004 as first-line therapy for mCRC in combi-
nation with IFL, bevacizumab has recently received a label 
extension in Europe and is now registered for combination 
with all standard fluoropyrimidine-based chemotherapies 
as first and later lines of therapy in patients with mCRC.
 The objective of this review is to describe the evolution 
of irinotecan-based regimens for mCRC and consider the 
impact on efficacy and tolerability of adding bevacizu-
mab to these regimens.
 Methods 
 Literature searches from large publication databases (PubMed, 
ASCO, ASCO GI, ESMO) were performed to capture key data rel-
evant to bevacizumab, irinotecan, and the treatment of CRC.
 Clinical Efficacy of Bevacizumab plus Irinotecan 
 The efficacy of bevacizumab combined with irinote-
can-based chemotherapies has been evaluated in a num-
ber of key clinical trials  [12, 14–31] .  Tables 1 and  2 high-
light the key efficacy data from these studies; all method-
ology has been previously reported and is not reiterated 
within this review.
 Bevacizumab plus IFL 
 The marked improvement in survival reported when 
irinotecan was combined with bolus 5-FU/LV  [6] led to 
this regimen (IFL) becoming the first-line standard of 
care in the USA in patients with mCRC. It was, therefore, 
notable that the pivotal phase III study of bevacizumab in 
mCRC (AVF2107g) showed that the addition of bevaci-
zumab to IFL significantly increased OS by 4.7 months 
compared with IFL plus placebo (20.3 vs. 15.6 months, 
respectively, HR = 0.66; p  ! 0.001)  [14] . Likewise, com-
pared with IFL plus placebo, bevacizumab in combination 
with irinotecan was associated with significantly longer 
PFS (median 10.6 vs. 6.2 months, respectively; HR = 0.54; 
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p  ! 0.001), higher response rate and longer duration of re-
sponse ( table  1 ). Notably, a retrospective, exploratory 
analysis demonstrated that the addition of bevacizumab 
to IFL achieved statistically significant improvements in 
PFS and OS regardless of objective tumor response  [32] .
 Following disease progression in AVF2107g, patients 
were unblinded and continued on second-line therapy at 
the discretion of the study investigator. Oxaliplatin-based 
regimens were not widely available in the USA at this 
time; however, of the patients who received oxaliplatin-
Table 1.  Efficacy results from clinical trials evaluating bevacizumab combined with irinotecan-based, first-line chemotherapy regi-
mens
Study Phase n Regimen Primary endpoint OS, months PFS, months ORR, %
AVF2107g [14] III 813 IFL + BEV
vs. IFL + placebo
OS 20.3 vs. 15.6 
(HR = 0.66; p < 0.001)
10.6 vs. 6.2 
(HR = 0.54; p < 0.001)
44.8 vs. 34.8
(p = 0.004)
MD Anderson [17] II 43 FOLFIRI + BEV PFS – 12.5 60
BICC-C [10, 18] II 117 FOLFIRI + BEV
vs. mIFL + BEV
PFS 28.0 vs. 19.2 
(HR for death = 1.79;
p = 0.037)
11.2 vs. 8.3 (p = 0.28) 57.9 vs. 53.3
NS
AIO 0604 [12] II 247 CAPOX + BEV
vs. CAPIRI + BEV
PFS 26.7 vs. not reached
(p = 0.55)
10.4 vs. 12.1 (p = 0.27) 53 vs. 55
GONO-
FOLFOXIRI [19]
II 57 FOLFOXIRI + BEV % patients 
progression-
free at 10 months
– – 75
PACCE  [20] III 230 IRI + BEV + pmab
vs. IRI + BEV
PFS 20.7 vs. 20.5 (HR = 1.42, 
95% CI: 0.77–2.62)
10.1 vs. 11.7 (HR = 1.19,
95% CI: 0.79–1.79)
43 vs. 40 (HR = 1.11,
95% CI: 0.65–1.90)
Ardalan et al. [21] II 22 IFL + BEV OS not reached 13.1 (lower 95% CI: 8.4) 66.7 (95% CI: 43.0–
85.4)
Vieitez et al. [22] II 85 CAPIRI + BEV – 22.3 (95% CI: 17.4–27.2) 15.0 (95% CI: 11.3–18.7) 65 (95% CI: 58–72)
Welch et al. [23] II 50 CAPIRI + BEV PFS – 11.1 (lower 95% CI:9.2;
n = 21)
40%
ACCORD [13] II 145 FOLFIRI + BEV
vs. CAPIRI + BEV
PFS at 6 months 23.0
23.0
9.0
9.0
59 (95% CI: 53–65)
54 (95% CI: 48–60)
B EV = Bevacizumab; CI = confidence interval; FOLFIRI = 5-FU/LV + irinotecan; IRI = irinotecan; NS = not significant; pmab = panitumumab.
Table 2.  Efficacy results from phase IV and observational studies evaluating bevacizumab combined with first-line irinotecan-based 
chemotherapy regimens
Study Phase n Regimen Primary
endpoint
OS, months PFS, months ORR, %
AVIRI [24] IV 209 FOLFIRI + BEV PFS 22.2 (95% CI: 20.5–25.9) 11.1 (95% CI: 10.3–12.1) 53.1
BEAT [25] Obs. 503 FOLFIRI + BEV safety 22.7 (95% CI: 21.7–25.9) 11.6 (95% CI: 10.8–12.5) –
BRiTE [26, 27] Obs. 468 FOLFIRI + BEV
IFL + BEV
safety 22.9 (95% CI: 19.6–27.4)
19.9 (95% CI: 16.9–23.8)
10.8 (95% CI: 9.7–11.7) 
9.0 (95% CI: 8.2–11.0)
–
–
Moehler et al. [28] II/ Obs. 46 CAPIRI + BEV vs. CAPIRI response 
rate
24 vs. 15 12.8 vs. 11.4 34.5 vs. 29.4
SICOG [29] Obs. 81 IRIFAFU + BEV – – 14.1 (95% CI: 9.6–18.6) 57 (95% CI: 45–68)
Degirmenci et al. [30] Obs. 53 CAPIRI + BEV – 20.6 8 1.7 12.6 8 1.4 43.3
Garcia Alfonso et al. 
[31]
Obs. 43 CAPIRI + BEV –
_
19.0 10.3 62.8
B EV = Bevacizumab; CI = confidence interval; FOLFIRI = 5-FU/LV + irinotecan; IRIFAFU = irinotecan, folinic acid, 5-FU; NR = not reported;
Obs. = observational study. 
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based chemotherapy, OS was longer for those who had 
originally received IFL plus bevacizumab (median 25.1 
months) compared with those who had received IFL plus 
placebo (22.2 months)  [14] .
 Results from AVF2107g were broadly similar to those 
with bevacizumab combined with first-line oxaliplatin-
based chemotherapy in patients with mCRC  [15] . When 
combined with 5-FU/LV plus oxaliplatin (FOLFOX) or 
capecitabine plus oxaliplatin (CAPOX), bevacizumab 
was associated with a significant increase in PFS com-
pared with placebo (from 9.4 vs. 8.0 months, respectively; 
p = 0.0023). Median OS was 21.3 months in the bevaci-
zumab group and 19.9 months in the placebo group, but 
this difference did not reach statistical significance. It 
should be noted, however, that only 29 and 47% of beva-
cizumab and placebo recipients, respectively, were treat-
ed until disease progression.
 The current data suggest that first-line therapy with 
bevacizumab plus two active chemotherapeutic agents 
followed by postprogression therapy with a third active 
chemotherapy regimen may be an improved manage-
ment strategy for mCRC. Furthermore, the survival ben-
efit observed with bevacizumab plus IFL may have been 
more pronounced if second-line oxaliplatin-based regi-
mens had been more widely available and used in this 
study. This aspect needs to be considered when reviewing 
recent data reports from randomized trials where the 
availability of later-line combination therapy has the po-
tential to impact on OS outcome.
 Bevacizumab plus FOLFIRI 
 Following the demonstrated survival benefit with the 
addition of bevacizumab to IFL and bevacizumab, it was 
necessary to assess whether these survival benefits were 
consistent across different irinotecan-containing regi-
mens to ensure that physicians could select the most ap-
propriate therapies for their patients. This was particu-
larly important, given the preference for IFL in the USA 
compared with the infusional FOLFIRI regimen in Eu-
rope and in light of data from several studies that indi-
cated the superior efficacy and improved safety of infu-
sional 5-FU compared with bolus 5-FU  [33, 34] . 
 AVIRI was a phase IV trial initiated at the request of 
the Swiss regulatory authorities to evaluate the safety and 
efficacy of bevacizumab in combination with FOLFIRI 
 [24] . The results from this trial indicated that bevacizu-
mab plus FOLFIRI was comparable in efficacy and safety 
to bevacizumab plus IFL  [14, 35] . Further support for the 
use of bevacizumab plus FOLFIRI also came from a phase 
II trial carried out by the MD Anderson Cancer Center, 
which showed that the addition of bevacizumab to FOL-
FIRI extended PFS by approximately 4 months compared 
with historical data for FOLFIRI alone  [17, 36] .
 Controlled evidence for the use of bevacizumab with 
irinotecan-based regimens has recently been gained from 
the BICC-C study  [10] . This was a phase III trial origi-
nally initiated to compare the safety and efficacy of FOL-
FIRI with modified IFL (mIFL) and CAPIRI in first-line 
mCRC (period 1). Following FDA approval of bevaci-
zumab, BICC-C was subsequently amended to allow the 
addition of bevacizumab to mIFL and FOLFIRI (period 
2). As previously observed in phase II/III clinical trials, 
the addition of bevacizumab to chemotherapy in BICC-C 
resulted in superior patient outcomes compared with re-
sults obtained with chemotherapy alone in period 1 of the 
trial  [10, 18] . Although no significant difference in PFS 
was detected between patients receiving bevacizumab 
plus either FOLFIRI or mIFL (p = 0.28;  table 1 ), median 
OS with bevacizumab plus FOLFIRI was 28 months, be-
ing significantly longer than for patients receiving beva-
cizumab plus mIFL (19.2 months; p = 0.037)  [18] .
 A subgroup analysis evaluated whether these treat-
ment regimens are effective in an older patient popula-
tion using a cutoff age of 70 years  [37] . Due to low patient 
numbers in the respective subgroups the statistical power 
was limited, but PFS did not differ significantly between 
age groups in all treatments combined when bevacizu-
mab was added to FOLFIRI or mIFL. In addition, there 
was no difference in OS between age groups for the over-
all cohort or within each treatment arm. Consistent with 
other recent reports  [38–40] , these data suggest that age 
does not affect the degree of benefit achieved from the 
addition of bevacizumab to chemotherapy and supports 
consideration of its use in an elderly patient population.
 Bevacizumab has also been evaluated in combination 
with 5-FU/LV plus both oxaliplatin and irinotecan 
(FOLFOXIRI). Safety data from an ongoing phase II trial 
suggest that this combination is feasible, with manage-
able toxicity and no unexpected adverse events  [19] . In a 
further study in 48 patients with mCRC, first-line beva-
cizumab plus FOLFOXIRI achieved a response rate of 
84% and median PFS and OS durations of 12 months 
(95% CI: 2–33 months) and 25 months (95% CI: 2–34 
months), respectively  [41] . These data have provided the 
rationale for a phase III trial directly evaluating bevaci-
zumab plus FOLFIRI compared with bevacizumab plus 
FOLFOXIRI, which is currently recruiting patients ( ta-
ble 3 )  [42] .
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 Second-Line Bevacizumab plus FOLFIRI 
 As a result of the widespread use of oxaliplatin in both 
adjuvant and first-line strategies for the treatment of 
mCRC, irinotecan is commonly utilized in second-line or 
subsequent regimens. In a pilot study enrolling 14 pa-
tients progressing after treatment with oxaliplatin and 
irinotecan, bevacizumab plus FOLFIRI demonstrated 
good activity, achieving a response rate of 28.5% (includ-
ing one complete response), median time to progression 
of 3.9 months (95% CI: 2.0–8.7 months), and median OS 
of 10.9 months (95% CI: 9.6–12.1 months)  [43] . In anoth-
er series of 31 heavily pretreated patients, bevacizumab 
plus FOLFIRI or FOLFOX administered as second-, 
third-, or later-line chemotherapy achieved an ORR of 
32.2%  [44] . The response rate in FOLFIRI-treated pa-
tients was 36.9% (7/19), while it was 25% (3/12) in FOL-
FOX-treated patients. These data support the clinical 
utility of combination therapy with bevacizumab and 
FOLFIRI as second- or later-line treatment in mCRC and 
provide a rationale for randomized clinical evaluation of 
the regimen in this setting.
 Bevacizumab plus CAPIRI 
 A range of clinical trials have evaluated bevacizumab 
in combination with capecitabine. These trials have dem-
onstrated that CAPIRI plus bevacizumab is an effective 
regimen in mCRC, with comparable activity to CAPOX 
plus bevacizumab ( tables 1 ,  2 )  [12, 13, 22, 23, 28] . The use 
of capecitabine with bevacizumab and irinotecan or ox-
aliplatin further expands the therapeutic options avail-
able for treating mCRC.
 The AIO trial comparing bevacizumab plus CAPOX 
and bevacizumab plus CAPIRI is a randomized study in 
patients with chemonaïve mCRC and an ECOG PS  ^  2 
 [12] . The CAPIRI regimen incorporated 20% dose reduc-
tion compared with regimens used in previous trials re-
porting unacceptable gastrointestinal toxicity  [10, 34] .
 At the time of analysis, 247 patients were evaluated 
who had received a median of 8 and 9 cycles of CAPOX 
(127 patients) and CAPIRI (120 patients), respectively 
 [12] . Treatment discontinuation has been documented for 
222 patients and attributed to disease progression in 36% 
(CAPOX/CAPIRI: 40%/32%), toxicity in 27% (CAPOX/
CAPIRI: 39%/16%) and the patient’s decision in 17% 
 (CAPOX/CAPIRI: 16%/19%). CAPOX and CAPIRI 
achieved similar response rates (53 and 55%, respective-
ly), similar tumor control rates (82 and 83%, respective-
ly) and 6-month PFS rates (76 and 84%, respectively).
Although median PFS was lower with CAPOX than
CAPIRI (10.4 vs. 12.1 months), this difference was not 
statistically significant (p = 0.27).
 In accordance with the data for comparison of first-
line combination with bevacizumab plus FOLFOX and 
FOLFIRI, these preliminary data support similar efficacy 
for CAPOX and CAPIRI. However, the tolerability pro-
files for CAPOX and CAPIRI differed substantially. 
While CAPOX and CAPIRI were associated with similar 
rates of grade 3/4 diarrhea (21 and 16%, respectively) and 
hand-foot syndrome (11 and 8%, respectively), grade 3/4 
sensory neuropathy was substantially increased with 
CAPOX compared with CAPIRI (24 vs. 1%)  [12] .
 The data from the AIO trial therefore demonstrated 
that while both regimens are highly active and safe, the 
absence of neuropathy favors bevacizumab plus CAPIRI 
in first-line mCRC.
 A formal comparison of CAPIRI plus bevacizumab 
versus FOLFIRI plus bevacizumab was carried out by the 
National    Federation   of   French   Cancer   Centres   within 
a randomized phase II trial (NCT00423696)  [13] . This 
study included 145 patients and indicated comparable re-
sponse rates (54 vs. 59%) and identical durations for PFS 
(9 months) and OS (23 months) for both regimens. Also 
the toxicity profiles were manageable and comparable. 
Table 3.  Ongoing and planned trials of bevacizumab plus irinote-
can in the first-line setting
Study (clinicaltrials.gov 
identifier)
Phase Patients
planned
Regimen
NCT00469443 III 330 arm A: BEV + FOLFIRI
arm B: BEV + CAPIRI
NCT00642603 II 280 arm A: BEV + CAPOX
arm B: BEV + CAPIRI
NCT00433927 III 568 arm A: BEV + FOLFIRI
arm B: CET + FOLFIRI
NCT00642577 III 210 arm A: BEV + FOLFIRI
arm B: FOLFIRI
Planned II 150 arm A: BEV + FOLFIRI
arm B: BEV + CAPIRI
NCT00483834 II 50 BEV + CAPIRI
NCT00719797 III 450 arm A: BEV + FOLFOXIRI
arm B: BEV + FOLFIRI
B EV = Bevacizumab; CET = cetuximab; FOLFIRI = 5-FU/LV 
+ irinotecan.
 Bevacizumab plus Irinotecan in mCRC Oncology 2010;79:118–128 123
Clinical adverse events observed in the CAPIRI and FOL-
FIRI arm such as grade 3–4 neutropenia (18 vs. 27%) and 
diarrhea (12 vs. 5%) were considered low and compared 
well to previous reports.
 Duration of Bevacizumab Therapy 
 The combination regimen of bevacizumab plus FOL-
FIRI or CAPIRI achieves remarkably consistent PFS in 
clinical trials ( table  1 ). Generally, median PFS ranges 
from 11 to 13 months  [12, 17, 18, 20, 21, 23] with median 
OS extending beyond 20 months, and despite being cross-
trial comparisons, these data appear similar to the 10.6 
and 20.3 months achieved for PFS and OS, respectively, 
in the pivotal trial with bevacizumab plus IFL  [14] . Like 
the pivotal study with IFL, the clinical studies with FOL-
FIRI/CAPIRI and bevacizumab (5 mg/kg/2 weeks or 7.5 
mg/kg/3 weeks) allowed treatment to disease progres-
sion. There is evidence to suggest that PFS with first-line 
chemotherapy for mCRC may be negatively impacted by 
reduced duration of bevacizumab therapy  [15, 24] . While 
inter-trial comparisons are undesirable, and data from 
randomized, controlled trials are limited, this observa-
tion, together with the manageable and noncumulative 
toxicity associated with bevacizumab, lend support to 
maintenance therapy with bevacizumab-based regimens. 
A further small, hypothesis-generating study has evalu-
ated the use of maintenance bevacizumab in 34 patients 
receiving CAPIRI plus bevacizumab as first- or second-
line treatment of mCRC  [45] . The ORR was 47.1%, with 
median PFS and OS of 8 and 14 months, respectively.
 Bevacizumab Treatment Beyond Disease 
Progression 
 Bevacizumab beyond disease progression has been 
 explored in the nonrandomized, observational BRiTE 
study  [26, 27] . The 1,953 patients registered to the study 
achieved median PFS and OS durations of 9.9 months 
(95% CI: 9.5–10.3 months) and 22.9 months (95% CI: 21.9–
24.4 months), respectively. Notably, in the 1,445 patients 
with documented disease progression, bevacizumab be-
yond disease progression was significantly associated with 
a prolonged survival (HR = 0.49; p  ! 0.001) on multivari-
ate analysis  [27] . Median OS was 12.6 months in the 253 
patients that had no further treatment, 19.9 months in the 
531 who had further treatment without bevacizumab and 
31.8 months in the 642 patients who received further che-
motherapy with bevacizumab. However, it should be not-
ed that BRiTE is an uncontrolled, observational study and, 
as such, these data can only be considered to be suggestive.
 As bevacizumab acts on stable endothelial cells, and 
not the frequently transforming cancer cells, there may 
be reduced potential for acquired resistance during the 
course of disease. However, there is some evidence that 
resistance can occur either by up-regulation of angiogen-
esis activators or bypassing vascular endothelial growth 
factor pathways to bevacizumab. There exists a need for 
prospective trials that assess the effect of continuing be-
vacizumab after progression of disease (with new chemo-
therapy combination partners). One such trial is a ran-
domized, international, open-label phase III study, spon-
sored by Roche (NCT00700102).
 Bevacizumab in Patients with Oncogenic Mutations 
 Various potentially prognostic or predictive markers 
have been proposed that identify patients with a likely 
poorer prognosis from those most likely to benefit from, 
or fail to respond to, a specific treatment. Recently, the 
well-established oncogene  K-ras  has received increasing 
attention as a marker due to evidence that demonstrates 
its negative prediction for the effectiveness of monoclonal 
antibodies targeting the epidermal growth factor recep-
tor in patients carrying a gene mutation.
 A retrospective analysis of data from 230 patients treat-
ed in the pivotal bevacizumab trial AVF2107g was carried 
out to determine whether mutations within  K-ras, b-raf  or 
p53 predict outcome in patients receiving bevacizumab 
 [46, 47] . The analysis suggested that bevacizumab provid-
ed survival benefit regardless of K-ras, b-raf  or p53  muta-
tion status  [46] . While a significantly higher response rate 
was observed with addition of bevacizumab only in  K-ras 
wild-type patients (60.0 vs. 37.3%, p = 0.006), PFS and OS 
benefits were conferred in both  K-ras mutant and wild-
type patients ( fig. 1 )  [47] . Notably, in a recent analysis of 
the PACCE trial, patients treated with irinotecan-based 
chemotherapy (FOLFIRI) and bevacizumab in the control 
arm achieved a median PFS that compares favorably to the 
majority of published data from controlled trials. The ad-
dition of the epidermal growth factor receptor antibody 
panitumumab to bevacizumab plus irinotecan-based che-
motherapy in this trial resulted in shorter PFS compared 
with bevacizumab plus chemotherapy only, which was 
also observed regardless of patients’  K-ras status (wild-
type  K-ras ; 10.0 vs. 12.5 months, respectively: mutant  K-
ras ; 8.3 vs. 11.9 months, respectively)  [20] .
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 Safety and Tolerability of Bevacizumab plus 
Irinotecan 
 Bevacizumab has a consistent and well-defined safety 
profile across tumor types. Although bevacizumab is as-
sociated with an increase in some specific adverse events, 
including hypertension, proteinuria, arterial thrombo-
embolic events, and gastrointestinal perforation ( table 4 ), 
severe grade 3/4 events are reported in low numbers for 
these toxicities and the majority of these events are gener-
ally mild to moderate in severity and manageable using 
standard therapies  [48] . Irinotecan has historically been 
associated with high levels of diarrhea  [5, 6, 49] , leading 
to some reservations concerning its use in first-line ther-
apy. Thus, it is of interest to note that during the first pe-
riod of the BICC-C study, FOLFIRI had the lowest inci-
dence of grade  6 3 diarrhea (13.9%) of all the irinotecan-
containing treatment arms. Further support for the use 
of irinotecan in a first-line setting came from the second 
phase of BICC-C during which the frequency of diarrhea 
did not increase following the addition of bevacizumab 
to FOLFIRI (10.7%)  [10] . Additionally, the incidence of 
grade 3/4 diarrhea was shown to be comparable between 
patients receiving bevacizumab plus CAPOX (21%) or re-
duced dose CAPIRI (16%) during the AIO 0604 trial  [12] . 
By reducing both the dose of capecitabine and irinotecan 
in this study, chemotherapy-related adverse events were 
minimized without compromising the efficacy of the 
CAPIRI regimen. Addition of bevacizumab to standard 
first-line chemotherapy does not significantly increase 
the incidence of chemotherapy-related toxicities com-
pared with chemotherapy alone  [14] .
 Future Directions of Bevacizumab plus Irinotecan 
 A number of ongoing or planned clinical trials will 
further evaluate the safety and efficacy of bevacizumab 
plus irinotecan-containing regimens for the first-line 
treatment of mCRC ( table 3 ). The recent approval of be-
vacizumab in combination with all fluoropyrimidine-
based standard chemotherapies as first and later lines of 
treatment for mCRC is likely to impact on current treat-
ment guidelines for the disease. This label extension pro-
vides both physicians and patients with increased treat-
ment options.
 Several studies have investigated the possibility of 
combining different biological therapies that target dif-
ferent pathways critical to tumorigenesis. The phase II 
BOND-2 trial, for example, indicated that the combina-
tion of the epidermal growth factor receptor inhibitor 
cetuximab with bevacizumab and irinotecan was asso-
ciated with clinical benefit  [50, 51] . Similarly, median 
PFS and OS durations of 8.7 and 12.1 months, respec-
tively, were reported in a recent Danish observational 
study in which bevacizumab was added after failure of 
third-line irinotecan plus cetuximab in 24 patients  [52] . 
These findings have not, however, been borne out in 
phase III studies. In the CAIRO2 study, the addition of 
cetuximab to bevacizumab plus CAPOX produced a sig-
nificant decrease in PFS compared with bevacizumab 
plus CAPOX alone (9.8 vs. 10.7 months, respectively;
p = 0.018)  [53] . Likewise, the addition of panitumumab 
to bevacizumab plus irinotecan-based chemotherapy in 
the PACCE study resulted in nominally lower PFS in the 
overall population (10.1 and 11.7 months for panitu-
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pendent of  K-ras mutation status  [47] . Re-
produced with permission of AlphaMed 
Press. 
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mumab-containing and bevacizumab-only arms, re-
spectively) and in both  K-ras subgroups  [20] . Therefore, 
there appears to be little advantage to combining either 
cetuximab or panitumumab with bevacizumab plus 
chemotherapy.
 Another area of research is the identification of pre-
dictive markers of response to treatment. Possible mark-
ers include blood and tumor markers such as vascular 
endothelial growth factor and other growth factors, as 
well as polymorphisms in key genes. To date, however, no 
clear predictive biomarker for bevacizumab treatment 
has emerged. In addition, imaging techniques such as dy-
namic contrast-enhanced magnetic resonance imaging, 
computed tomography and positron emission tomogra-
phy have the potential to provide a noninvasive way of 
evaluating biomarkers and predicting treatment re-
sponse.
 Limitations of Data 
 Although clinical trials demonstrate significant im-
provements in patient outcomes following the addition of 
bevacizumab to irinotecan, it is important to note that 
the available data are still somewhat limited. The only 
phase III data currently available are from the AVF2107g 
trial  [14] , while the majority of the other trials evaluating 
bevacizumab plus irinotecan are single arm only or do 
not have a randomized control arm  [17, 25] .
 In addition, the two largest trials in terms of patient 
numbers, BEAT and BRiTE, are nonrandomized, obser-
vational studies  [25–27] . However, considering these lim-
itations, the unprecedented results from AVF2107g in 
conjunction with the wealth of available data support the 
use of bevacizumab in combination with irinotecan-con-
taining regimens in patients with mCRC. Data from on-
going/upcoming trials will provide further insights into 
the important role of this regimen in this disease setting. 
Table 4.  Adverse events of special interest for bevacizumab in clinical and community-based trials
Study Regimen G rade ≥3 adverse events of special interest for bevacizumab, %
hypertension proteinuria bleeding ATE VTE GI perforation
AVF2107g [14] IFL + Placebo 2.3 0.8 2.5         16.2a 0
IFL + BEV 11 0.8 3.1         19.4a 1.5
AVIRI [24] FOLFIRI + BEV 5 2 4 4 18 2
MD Anderson [17] FOLFIRI + BEV 8 0 0 – 7 0
BICC-C [10] mIFL + BEV 1.7 – – – – –
FOLFIRI + BEV 12.5 – – – – –
BEAT [25] FOLFIRI + BEV 3 1 3 1 – 2
Moehler et al. [28] CAPIRI – 0 – 0 0 –
CAPIRI + BEV – 3.4 – 0 0 –
AIO 0604 [12] CAPIRI + BEV 3 – 0 – – 1
CAPOX + BEV 4 – 1 – – 0
Ardalan et al. [21] IFL + BEV – – – 0 4.5 0
SICOG [29] IRIFAFU + BEV 1 – – – – –
Garcia Alfonso et al. [31] CAPIRI + BEV 2b 0 – 2a – 0
ACCORD [13] FOLFIRI + BEV
CAPIRI + BEV
8c
3c
1
1
0
2
0
0
3
12
1
0
Welch et al. [23] CAPIRI + BEV 10 – – – 4 2
ATE = Arterial thromboembolic event; BEV = bevacizumab; FOLFIRI = 5-FU/LV + irinotecan; GI = gastrointestinal; IRIFAFU = 
irinotecan, folinic acid, 5-FU; VTE = venous thromboembolic event.
a Thromboembolic events of any grade. b Estimated from data presented graphically. c Includes hypotension as well as hypertension.
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Furthermore, it also needs to be determined whether per-
mutations within given regimens reflect a justifiable need 
for large-scale controlled clinical trials in light of an in-
creasingly complex and resource-limited environment.
 Conclusions 
 Irinotecan-containing combinations have been an in-
tegral part of the treatment for mCRC for over a decade 
now, and they serve as excellent platforms for the addi-
tion of new molecular targeted therapies. The addition of 
bevacizumab to irinotecan improves outcomes in pa-
tients with mCRC, and its efficacy does not appear to be 
influenced by  K-ras mutational status. Bevacizumab has 
a well-established safety profile and the toxicities associ-
ated with its use are usually mild in severity and easily 
manageable. Bevacizumab in combination with irinote-
can-containing regimens is effective and should be con-
sidered an important therapy option for the treatment of 
mCRC.
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